Thrombo ACS, 50 mg 100 pcs

Pharmaceutical group:

NAPs.

Pharmic action:

NPS. The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase, resulting in blocking the synthesis of thromboxane A2 and inhibiting platelet aggregation.

It is believed that there are other mechanisms of inhibition of platelet aggregation, which expands the field of its application in various vascular diseases.

It also has anti-inflammatory, analgesic and antipyretic effects.

Indications

– prevention of acute myocardial infarction in the presence of risk factors (such as diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age);

— secondary prevention of myocardial infarction;

– unstable angina;
— prevention of stroke (including in patients with transient cerebrovascular accidents);
— prevention of transient cerebrovascular accidents;
– prevention of thromboembolism after operations and invasive interventions on blood vessels (such as coronary artery bypass surgery, carotid endarterectomy, arteriovenous bypass, carotid angioplasty);
– prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (for example, with prolonged immobilization as a result of major surgery).

Pharmacological effect

Pharmgroup:

NSAIDs.

Pharmaceutical action:

NSAIDs. The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase, as a result of which the synthesis of thromboxane A2 is blocked and platelet aggregation is suppressed.

It is believed that there are other mechanisms for suppressing platelet aggregation, which expands the scope of its application in various vascular diseases.

It also has anti-inflammatory, analgesic and antipyretic effects.

Special instructions

ASA can provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, as well as allergic reactions to other drugs (itching, urticaria).

ASA can cause bleeding of varying severity during and after surgery.

The combination of ASA with anticoagulants, thrombolytics, and antiplatelet agents is accompanied by an increased risk of bleeding.

ASA in low doses can trigger the development of gout in predisposed individuals with reduced excretion of uric acid.
The combination of ASA with methotrexate is accompanied by an increased incidence of side effects from the hematopoietic system.
High doses of ASA have a hypoglycemic effect, which must be taken into account when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.

When combined with GCS, it should be remembered that during treatment the level of salicylates in the blood is reduced, and after discontinuation of GCS, an overdose of salicylates is possible.

The combination of ASA with ibuprofen is not recommended, since the latter worsens the beneficial effect of ASA on life expectancy.
When combining ASA with alcohol, there is an increased risk of damage to the gastrointestinal mucosa and prolongation of bleeding time.

Active ingredient

Acetylsalicylic acid

Composition

1 tab.:
– acetylsalicylic acid 50 mg or 100 mg

Excipients:

lactose,

microcrystalline cellulose,

colloidal silicon dioxide,

potato starch,

talc,

triacetin,

silicone antifoaming agent SE2,

Eudrajit L30D (methacrylic acid and ethacrylate copolymer).

Contraindications

– erosive and ulcerative lesions of the gastrointestinal tract, gastrointestinal bleeding;
— “aspirin” asthma (bronchial asthma induced by taking salicylates and NSAIDs);
— “aspirin triad” (a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid);
– hemorrhagic diathesis;
– combined use with methotrexate at a dose of 15 mg or more per week;
— I and III trimesters of pregnancy;
– lactation (breastfeeding);
– children and adolescents up to 18 years of age;
– hypersensitivity to acetylsalicylic acid, to the excipients of the drug Thrombo ACC and other NSAIDs.

Prescribed with caution for gout, hyperuricemia, a history of ulcerative lesions of the gastrointestinal tract or bleeding from the gastrointestinal tract, renal and liver failure, bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, a history of allergic reactions to drugs, when used simultaneously with methotrexate at a dose of 15 mg or less per week.

Side Effects

Allergic reactions: urticaria, Quincke’s edema, anaphylactic reactions.

From the digestive system: nausea, heartburn, vomiting, abdominal pain, ulcers of the gastric and duodenal mucosa (including perforated ones), increased activity of liver enzymes.

From the respiratory system: bronchospasm.

From the hematopoietic system: anemia (rarely), increased bleeding.

From the side of the central nervous system: dizziness, tinnitus.

In general, Thrombo ACC® is well tolerated by patients (due to the low content of acetylsalicylic acid in the drug). Side effects have been reported in isolated cases.

Interaction

When used simultaneously, Thrombo ACC® enhances the effect of the following drugs:

— methotrexate by reducing renal clearance and displacing it from protein binding;
– heparin and indirect anticoagulants due to disruption of platelet function and displacement of indirect anticoagulants from binding with proteins;
— thrombolytic and antiplatelet agents (ticlopidine);
— digoxin due to a decrease in its renal excretion;
– hypoglycemic agents (insulin and sulfonylurea derivatives) due to the hypoglycemic properties of ASA itself in high doses and the displacement of sulfonylurea derivatives from bonds with proteins;
– valproic acid due to its displacement from bonds with proteins.

An additive effect is observed when taking ASA simultaneously with ethanol.

ASA weakens the effect of uricosuric drugs (benzbromarone) due to competitive tubular elimination of uric acid.
With simultaneous use of GCS, they enhance the excretion of salicylates and weaken their effect.

Overdose

Overdose is unlikely due to the low ASA content in the drug. Exceeding the dose of ASA is associated with a risk of gastrointestinal bleeding. Overdose is especially dangerous in elderly patients.

Symptoms: nausea, vomiting, tinnitus, dizziness, confusion, general malaise.

Treatment: artificial vomiting, administration of activated carbon, laxatives; if necessary, correct the acid-base balance.

Storage conditions

The drug should be stored in a dry place, protected from light, out of the reach of children, at a temperature not exceeding 25°C.

Shelf life

3 years.

Manufacturer

G.L.Pharma GmbH, Austria